Dermatology Times is recapping our top expert interviews from the month of March.
Nitin Joshi, PhD, shared CAGE Bio’s development of CGB-500 and why phase 2 EASI scores have the company’s scientific advisory board optimistic.
Following the announcement of Valisure's findings related to benzene and benzoyl peroxide acne products, Dermatology Times spoke with David Light, co-founder and president of the laboratory behind the report, to discuss the findings, the role of stability testing requirements, and quelling fear-filled online discourse.
Today is International Women's Day. Dermatology Times spoke with 5 women clinicians in the field to discuss the influences and advice that brought them to where they are today.
Maggi Ahmed, MD, PhD, demonstrated superior pigmentation outcomes and reduced CD8+ T cell numbers in her recent research results.
In celebration of Women's History Month and today, which is International Women's Day, dermatologist Nicole Negbenebor, MD, discusses her journey in the dermatology space and provides advice for young women and girls aspiring to enter the medical field.
"We cannot do health equity outside of an institution unless we figure out how to get our own house in order," the AMA leader said.
Chovatiya acknowledged the common sentiment among residents who, despite dedicating significant time to studying and working during residency, may feel unprepared.
Neal Bhatia, MD, shares his insights on successfully navigating AAD and his session highlights on office politics.
Lio delves into his American Academy of Dermatology Annual Meeting session, "Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach."
The American Acne and Rosacea Society welcomed Del Rosso as its new president and he shared key takeaways from his AAD sessions.
Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.
Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.
In addition to recapping key highlights from his session, Friedman discusses what is new or upcoming in dermatology that most excites him.
The phase 3 studies, BE HEARD I and BE HEARD II, showed significant improvements in skin pain over the 48-week period.
Discover the science behind cosmeceutical advancements and the importance of staying informed for enhanced patient care with Zoe Diana Draelos, MD.
The congenital ichthyosis session the 2024 AAD Annual Meeting covered real-world patient cases and treatments on the horizon.
Joseph Zabinski, PhD, MEM, of OM1, shares insights at AAD into how artificial intelligence can mature and be a positive tool for disease detection.
Eichenfield discusses the late-breaking data on roflumilast cream 0.05% in the pediatric patient population and its implications.
Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.
Burnett recently spoke with Dermatology Times to discuss the background, methods, and findings of the late-breaking INTEGUMENT-PED data, as well as its potential real-world and clinical implications.
Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.
In an exclusive interview with Gary Dudzik, he shared top 5 considerations dermatology clinicians should have when choosing financial services for their practices and overall financial goals.
Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.
Gallo presented pearls on the pathophysiology of acne and how newer studies have changed acne treatment methodologies at AAD 2024.
Jenny Murase, MD, said the average dermatologist manages 2-3 patients with delusional infestations every 5 years. Learn what to expect and how to manage it with empathy.
Lio spoke with Dermatology Times to discuss his sessions at AAD 2024, including addressing systemic malignancies with alternative or adjunctive therapies and the importance of minimizing pain in dermatology procedures.
Mona Shahriari, MD, presented real-world data on the efficacy of IL-23 inhibitors for psoriasis, as well as shared her advice from the Bristol Myers Squibb Women’s Connection Forum.
Waibel shared pearls in laser therapy and other scar treatment modalities in her talks at the American Academy of Dermatology Annual Meeting.
Menes Kizoulis shared key highlights from the research conducted alongside leading dermatologists, like Alan Irvine, MD, DSc, and Patricia Farris, MD, MS.
Naiem Issa, MD, PhD, emphasized the importance of increased awareness regarding antibiotic stewardship among dermatologists, as well as the recently updated acne guidelines.
Swanson shared updates and a look ahead and what's in store for the field of pediatric dermatology.
Shawn Kwatra, MD, shares positive updates on phase 2 oral povorcitinib for prurigo nodularis at AAD 2024.
Frey discussed the role of various cosmeceuticals and ingredients in benefitting the skin health of patients, as well as insights into pairing OTC products with Rx.
Raj Chovatiya, MD, PhD, delves into the conditions that could be red, itchy, and not atopic dermatitis. He explains the importance of knowing characteristics for various inflammatory conditions.
In between sessions, Lal shared his favorite pearls from AAD, a recent challenging pediatric case in his practice, the significance of LinkedIn, and more.
Ronda Farah, MD, FAAD, reviews top hair loss pearls from her 5 sessions at AAD 2024.
Founder Dina El-Sherif, MBA, gave an in-depth overview of the at-home facial rejuvenation device and its 3-step process at AAD 2024.
Allergist immunologist Giselle Mosnaim, MD, recently spoke with Dermatology Times to discuss late-breaking phase 3 REMIX-1 and REMIX-2 data presented at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.
With 30 years of clinical dermatology research under her belt, Draelos responds to recent benzene and BPO news in this Q&A.
Den, the chief medical officer of Alpha Tau, discusses the alpha particle-emitting atom treatment and its ability to target cancer cells without harming healthy tissue.
We spoke with several dermatology experts to gauge their thoughts on Valisure's recent findings of benzene in benzoyl peroxide products--as well as what actions they plan to take moving forward.
Dermatology Times recently spoke with Latanya Benjamin, MD, FAAD, FAAP, the newly-appointed president of the WDS, to discuss her hopes and goals for her presidency.
Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.
Spizuoco shares pearls from her sessions, "Infectious Diseases: The Story Behind STDs," and "Everything You Need to Know About Dermatopathology and the Dermatopathologist," from the Diversity in Dermatology conference.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
